Interpretation of Clinical Practice Guidelines for Management of Kidney Injury During Anticancer Drug Therapy 2022 (Ⅲ): evaluation of kidney function in patients undergoing anticancer drug therapy(Part 2)
10.3760/cma.j.cn114015-20240507-00308
- VernacularTitle:《抗肿瘤药物治疗期间肾损伤管理临床实践指南（2022）》解读（三）：抗肿瘤药物治疗患者的肾功能评估（第2部分）
- Author:
Yina WANG
1
;
Li ZUO
1
;
Yu YAN
1
Author Information
1. 北京大学人民医院肾内科，北京 100044
- Publication Type:Journal Article
- Keywords:
Antineoplastic agents;
Acute kidney injury;
Renal insufficiency;
Guideline;
Interpretation
- From:
Adverse Drug Reactions Journal
2024;26(7):385-389
- CountryChina
- Language:Chinese
-
Abstract:
Due to the characteristics of cytotoxicity, vascular toxicity, and immunotoxicity, anticancer drugs may be more likely to cause kidney injury than other drugs. It is an important content in anti-tumor treatment to fully understand the clinical manifestations and risk factors of anticancer drug-related renal injury, and evaluate the disease severity reasonably, so as to better adjust the anticancer schedule. Thus, the Japanese Society of Nephrology, Japan Society of Clinical Oncology, Japanese Society of Medical Oncology, and Japanese Society of Nephrology and Pharmacotherapy have jointly formulated the Clinical Practice Guidelines for Management of Kidney Injury During Anticancer Drug Therapy 2022 and made special discussions and suggestions on the definition, evaluation methods, main clinical manifestations, and risk factors of drug-induced kidney injury in cancer patients after receiving anticancer drug treatments. This article interprets this part of the content in order to make more effective guidance in clinical practice.
